Anticubilin antisense RNA ameliorates adriamycin-induced tubulointerstitial injury in experimental rats

Jun Liu1, Kailong Li, Yani He

  • 1Department of Nephrology, Daping Hospital, Research Institute of Surgery, Third Military Medical University, Chongqing, China.

Insights

Anticubilin antisense RNA therapy reduced kidney injury and improved function in proteinuric rats. This approach targets cubilin, showing potential for treating proteinuric nephropathy.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Genetics

Background:

  • Adriamycin-induced nephropathy is characterized by proteinuria and tubulointerstitial damage.
  • Cubilin is a protein involved in albumin reabsorption in renal tubules.
  • Targeting cubilin may offer a novel therapeutic strategy for proteinuric kidney diseases.

Purpose of the Study:

  • To investigate the therapeutic effects of anticubilin antisense RNA on adriamycin-induced proteinuric rats.
  • To assess the impact of anticubilin antisense RNA on albumin uptake, tubulointerstitial injury, and kidney function.
  • To evaluate cubilin as a potential therapeutic target in proteinuric nephropathy.

Main Methods:

  • Adriamycin-induced proteinuric rat model.
  • Intrarenal delivery of adenoviral vectors encoding anticubilin antisense RNA (pAd-ACUB).
  • Assessment of serum creatinine, glomerular filtration rate, albuminuria, kidney histology, and cubilin protein expression at days 14 and 28.

Main Results:

  • Anticubilin antisense RNA treatment significantly decreased serum creatinine and improved glomerular filtration rate.
  • Treatment led to an 85% knockdown in cubilin protein expression and reduced albumin deposition.
  • Histological analysis showed significant attenuation of tubulointerstitial damage and inflammatory markers.

Conclusions:

  • Anticubilin antisense RNA delivered via adenoviral vectors ameliorates adriamycin-induced nephropathy.
  • Cubilin plays a critical role in albuminuria-induced glomerulosclerosis and tubulointerstitial damage.
  • Cubilin represents a promising therapeutic target for proteinuric nephropathies.